The IBD Disability Index should become a Major Secondary Endpoint in Clinical Practice and in Clinical Trials.
INSERM U954 and Department of Hepatogastroenterology, Université de Lorraine, Allée du Morvan, F-54511 Vandœuvre-lès-Nancy, France peyrinbiroulet@gmail.com.
Laurent
L
Peyrin-Biroulet
Public Health, Epidemiology and Economic Health, EPIMAD registry, Regional House of Clinical Research, University Hospital, 59000, Lille, France.|International Center of Inflammation Research LIRIC-UMR 995 INSERM/University Hospital; "IBD and Environmental Factors: Epidemiology and Functional Analyses" Group, 59000, Lille, France.
Corinne
C
Gower-Rousseau
D000328:Adult; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000628:therapy; D003424:Crohn Disease / Q000175:diagnosis / Q000628:therapy; D004185:Disability Evaluation; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis* / Q000628:therapy; D011788:Quality of Life; D011795:Surveys and Questionnaires